THE ACCEPTANCE OF A 7-WEEK CYCLE WITH A MODERN LOW-DOSE ORAL-CONTRACEPTIVE (MINULET)

Cycle control and tolerance were studied in a group of 55 female volunteers, who took during 42 consecutive days a modern low-dose oral contraceptive: gestodene 75-mu-g/ethinylestradiol 30-mu-g (Minulet(R)). During these 42 days, 96% of the women experienced no breakthrough bleeding and 81% of the women experienced no spotting or breakthrough bleeding. When the findings of this study are compared with the findings of an earlier study with also a seven-week cycle but with other oral contraceptives, it can be concluded that Minulet(R) offered an excellent cycle control.